Preclinical data on Xeltis’ restorative heart valve technology will feature at the 16th International Society of Applied Cardiovascular Biology (ISACB) Biennial meeting.

Professor Frederick J. Schoen from Harvard Medical School will present 1-year preclinical data outlining the capability of Xeltis technology to restore heart valves and blood vessels through Endogenous Tissue Restoration (ETR).

The ISACB meeting will be held at the Palais de la Bourse in Bordeaux, France from September 16 – 19, 2018. For more information on this year’s edition “News Horizons and Challenges in Translational and Applied Cardiovascular Science” please visit: